Agenus Inc.
$4.42
▼
-2.06%
2026-04-21 05:08:01
www.agenusbio.com
NCM: AGEN
Explore Agenus Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$175.86 M
Current Price
$4.42
52W High / Low
$7.34 / $1.6
Stock P/E
1,529.26
Book Value
$-7.68
Dividend Yield
—
ROCE
21.26%
ROE
-0.04%
Face Value
—
EPS
$0
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
81
Beta
1.61
Debt / Equity
-0.21
Current Ratio
0.41
Quick Ratio
0.41
Forward P/E
-1.72
Price / Sales
1.33
Enterprise Value
$198.23 M
EV / EBITDA
-18.78
EV / Revenue
1.74
Rating
Strong Buy
Target Price
$15.5
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Strong operating margin profile.
Cons
- Return on equity is on the weaker side.
- Current ratio suggests tighter short-term liquidity.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lunai Bioworks Inc. | $0.34 | — | $12.33 M | — | 88.63% | -3.66% | $5.5 / $0.15 | $-0.56 |
| 2. | Pluri Inc. | $3.59 | — | $36.08 M | — | -348.95% | 669.52% | $7.13 / $2.82 | $-1.46 |
| 3. | LB Pharmaceuticals Inc | $31.67 | — | $875.16 M | — | -9.95% | -15.7% | $30.72 / $13.36 | $11.91 |
| 4. | MediciNova, Inc. | $1.47 | — | $71.37 M | — | -31.77% | -25.5% | $1.96 / $1.17 | $0.84 |
| 5. | Apogee Therapeutics, Inc. | $90.92 | — | $6.41 B | — | -31.41% | -31.57% | $95.31 / $31.38 | $13.21 |
| 6. | PMGC Holdings Inc. | $3.32 | — | $6.35 M | — | -76.42% | -1.07% | $309.12 / $1.62 | $97.11 |
| 7. | Disc Medicine, Inc. | $71.41 | — | $2.74 B | — | -30.64% | -35.86% | $99.5 / $39.2 | $19.52 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 34.2 M | 30.23 M | 25.69 M | 24.07 M | 26.84 M | — |
| Operating Profit | 14.4 M | -4.86 M | -16.78 M | -13.31 M | -27.99 M | — |
| Net Profit | -10.58 M | 63.91 M | -27.95 M | -25.27 M | -45.86 M | — |
| EPS in Rs | -0.28 | 1.66 | -0.73 | -0.66 | -1.19 | -3.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 114.2 M | 103.46 M | 156.31 M | 98.02 M |
| Operating Profit | -20.56 M | -124.43 M | -160.1 M | -180.24 M |
| Net Profit | 0.12 M | -227.21 M | -245.76 M | -220.07 M |
| EPS in Rs | 0 | -5.92 | -6.4 | -5.73 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 226.8 M | 226.27 M | 313.91 M | 413.56 M |
| Total Liabilities | 504.66 M | 532.7 M | 462.3 M | 468.46 M |
| Equity | -271.11 M | -326.38 M | -160.33 M | -61.28 M |
| Current Assets | 133.44 M | 45.57 M | 112.42 M | 213.12 M |
| Current Liabilities | 323.49 M | 221.4 M | 255.9 M | 188.95 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -77.19 M | -158.31 M | -224.2 M | -175.37 M |
| Investing CF | 1.19 M | 0.03 M | 3.4 M | -33.61 M |
| Financing CF | 36.59 M | 122.84 M | 119.87 M | 95.83 M |
| Free CF | -77.2 M | -158.89 M | -234.16 M | -228.44 M |
| Capex | -0.01 M | -0.58 M | -9.95 M | -53.06 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -33.81% | 59.47% | — | — |
| Earnings Growth % | 7.55% | -11.67% | — | — |
| Profit Margin % | -219.61% | -157.22% | -224.51% | — |
| Operating Margin % | -120.26% | -102.43% | -183.88% | — |
| Gross Margin % | -50.79% | -52.05% | -101.24% | — |
| EBITDA Margin % | -97.91% | -93.35% | -165.11% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-04-12 | 1:0.05 |
| 2023-04-26 | 1:1.019 |